StockData
Axsome Therapeutics, Inc. logo

Axsome Therapeutics, Inc. (AXSM) stock analysis

AXSMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 2, 2026Score 8/30
$141.69−2.68 (-1.86%)

Close on Nov 13, 2026Market cap $7.42BP/E –Yield –

StockData Score

Prices as of Nov 13, 2026How the score works

Value0Growth3Performance2Health3Dividend0

Weak8 of 30 checks passed

Axsome Therapeutics passes 8 of the 30 checks behind our score; 15 could not be run for lack of data and count as not passed. Each dot in the shape is one check — hover it for the numbers.

Valuation
0/6
Growth
3/6
Past performance
2/6
Financial health
3/6
Dividend
0/6

What stands out

  • Revenue growing 10%+ a year

    Revenue grew 134% a year over the last three fiscal years.

  • Interest well covered

    No meaningful interest expense to cover.

  • Low bankruptcy risk

    The Altman Z-score is 4.50; above 3 is the safe zone and below 1.8 the distress zone.

  • Growing faster than the industry

    Revenue grew 54.2% over the last twelve months; the Drugs median is 7.7%.

What to watch

  • Return on equity under 15%

    Return on equity was -176% over the last twelve months and averaged -229% over five years; we look for 15% on both.

  • High debt

    Debt is 178% of shareholders' equity, above the 40% we consider low.

  • Debt not well covered by cash flow

    Operating cash flow over the last twelve months equals -43.5% of total debt; we look for at least 20%.

  • P/B above the industry

    Axsome Therapeutics's price-to-book of 70.39 is above the Drugs median of 2.09.

Valuation0/6

  • P/E against its history

    Not enough price and earnings history to compare.

  • P/E against the industry

    Needs positive earnings and enough profitable companies in the industry.

  • EV/EBITDA against its history

    Needs positive EBITDA and price history.

  • P/B above the industry

    Axsome Therapeutics's price-to-book of 70.39 is above the Drugs median of 2.09.

  • Price against fair value

    We could not estimate a fair value: it needs at least two valuation methods with positive inputs.

  • Margin of safety

    Depends on the fair value estimate.

Growth3/6

  • Revenue growing 10%+ a year

    Revenue grew 134% a year over the last three fiscal years.

  • EPS growth over 3 years

    Needs positive EPS three years ago and today.

  • Earnings acceleration

    Needs positive net income now, a year ago and five years ago.

  • Growing faster than the industry

    Revenue grew 54.2% over the last twelve months; the Drugs median is 7.7%.

  • Company guidance

    No outlook found in earnings releases from the last twelve months.

  • Gross margin improving

    Gross margin was 93.2% over the last twelve months, against 91.9% a year earlier.

Past performance2/6

  • Return on equity under 15%

    Return on equity was -176% over the last twelve months and averaged -229% over five years; we look for 15% on both.

  • Return on invested capital

    Needs operating income and invested capital.

  • Return on equity below the industry

    Axsome Therapeutics's return on equity of -176% is below the Drugs median of -57.0%.

  • Earnings over 5 years

    Needs positive net income five years ago and in the latest year.

  • Net margin above its 5-year average

    Net margin was -18.2% over the last twelve months, against a 5-year average of -141%.

  • Net margin above the industry

    Axsome Therapeutics's net margin of -18.2% is above the Drugs median of -53.5%.

Financial health3/6

  • High debt

    Debt is 178% of shareholders' equity, above the 40% we consider low.

  • Debt rising against equity

    Debt to equity rose from 42.5% five years ago to 178%.

  • Debt not well covered by cash flow

    Operating cash flow over the last twelve months equals -43.5% of total debt; we look for at least 20%.

  • Interest well covered

    No meaningful interest expense to cover.

  • Short-term assets cover short-term debts

    Current assets are 1.42 times current liabilities.

  • Low bankruptcy risk

    The Altman Z-score is 4.50; above 3 is the safe zone and below 1.8 the distress zone.

Dividend0/6

  • No dividend

    Axsome Therapeutics has not paid a dividend in the last twelve months.

  • Yield against Treasuries

    No dividend.

  • Yield against the market

    No dividend.

  • Dividend stability

    No dividend.

  • Earnings cover

    No dividend.

  • Cash-flow cover

    No dividend.

Scores of similar companies

Fair value

How we estimate it

We don't publish a fair value for Axsome Therapeutics. It needs a US-dollar share price, at least two valuation methods with positive inputs (earnings, EBITDA, book value or sales) and, for companies with several share classes, classes that trade at the same price.

Valuation over time

Using the earnings and balance sheet published at each date, not today's.

  • EV/EBITDA at month end
  • Drugs median 17.4

An estimate from reported numbers and market multiples, not a price target or investment advice. It can be far off for companies whose profits are about to change sharply.

Market risk

From the past year of daily prices.

Liquidity

Low risk

Average value traded per day
$161.94M
Value traded per 1% price move
$70.43M

Downside

Medium risk

Typical loss in a bad month
24.1%
Volatility (annualized)
46%
Sharpe ratio, 1 year
-0.09
Beta to the S&P 500 (5Y)
0.51

Typical bad-month loss, week by week

25%: high

Margins

Share of revenue, fiscal years 2013 to 2025

Gross margin

92.6%

Operating margin

-26.1%

Net margin

-28.7%

See a number that looks wrong?